The treatment of cognitive impairment in schizophrenia

Donald C. Goff; Michele Hill; Deanna Barch

doi:10.1016/j.pbb.2010.11.009

The treatment of cognitive impairment in schizophrenia

Donald C. Goff, Michele Hill, Deanna Barch

Research output: Contribution to journal › Article › peer-review

134 Scopus citations

Abstract

Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.

Original language	English
Pages (from-to)	245-253
Number of pages	9
Journal	Pharmacology Biochemistry and Behavior
Volume	99
Issue number	2
DOIs	https://doi.org/10.1016/j.pbb.2010.11.009
State	Published - Aug 2011

Keywords

Clinical trials
Cognition
Drug development
Pharmacology
Schizophrenia

Access to Document

10.1016/j.pbb.2010.11.009

Cite this

@article{b509a494ab1247e6985f673cc4641e74,

title = "The treatment of cognitive impairment in schizophrenia",

abstract = "Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.",

keywords = "Clinical trials, Cognition, Drug development, Pharmacology, Schizophrenia",

author = "Goff, {Donald C.} and Michele Hill and Deanna Barch",

year = "2011",

month = aug,

doi = "10.1016/j.pbb.2010.11.009",

language = "English",

volume = "99",

pages = "245--253",

journal = "Pharmacology, Biochemistry and Behavior",

issn = "0091-3057",

number = "2",

}

TY - JOUR

T1 - The treatment of cognitive impairment in schizophrenia

AU - Goff, Donald C.

AU - Hill, Michele

AU - Barch, Deanna

PY - 2011/8

Y1 - 2011/8

N2 - Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.

AB - Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.

KW - Clinical trials

KW - Cognition

KW - Drug development

KW - Pharmacology

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79958274304&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2010.11.009

DO - 10.1016/j.pbb.2010.11.009

M3 - Article

C2 - 21115035

AN - SCOPUS:79958274304

SN - 0091-3057

VL - 99

SP - 245

EP - 253

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

IS - 2

ER -

The treatment of cognitive impairment in schizophrenia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this